Compare · BDX vs MCK
BDX vs MCK
Side-by-side comparison of Becton Dickinson and Company (BDX) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BDX focuses on Medical/Dental Instruments, while MCK focuses on Other Pharmaceuticals.
- MCK is the larger of the two at $104.74B, about 2.1x BDX ($48.79B).
- Over the past year, BDX is down 5.7% and MCK is up 30.9% - MCK leads by 36.6 points.
- MCK has been more active in the news (15 items in the past 4 weeks vs 11 for BDX).
- Both have 25 recent analyst ratings on file.
- Company
- Becton Dickinson and Company
- McKesson Corporation
- Price
- $177.04+3.78%
- $870.73-0.83%
- Market cap
- $48.79B
- $104.74B
- 1M return
- +17.65%
- +6.42%
- 1Y return
- -5.66%
- +30.90%
- Industry
- Medical/Dental Instruments
- Other Pharmaceuticals
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 11
- 15
- Recent ratings
- 25
- 25
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest BDX
- SEC Form 4 filed by Director Huffines Robert Luther
- SEC Form 4 filed by Director Byington Carrie L
- SEC Form 10-Q filed by Becton Dickinson and Company
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BD Reports Third Quarter Fiscal 2026 Financial Results
- EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch
- BD Board Declares Dividend
- EVP, Chief Revenue Officer Feld Michael sold $11,785 worth of shares (75 units at $157.13) as part of a pre-agreed trading plan, decreasing direct ownership by 0.36% to 20,934 units (SEC Form 4)
- UBS initiated coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
Latest MCK
- SEC Form 10-Q filed by McKesson Corporation
- McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
- McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- McKesson Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Hinton James H.
- SEC Form 4 filed by Director Doughtie Lynne M
- Director Wilson-Thompson Kathleen was granted 277 shares, increasing direct ownership by 92% to 578 units (SEC Form 4)
- SEC Form 4 filed by Director Dunbar Webster Roy
- Director Caruso Dominic J was granted 277 shares, increasing direct ownership by 43% to 927 units (SEC Form 4)
- SEC Form 4 filed by Director Gerberding Julie L.